Pfizer (PFE) Stock Rises as Monthly Weight-Loss Drug Data Impresses
TLDR Pfizer unveiled Phase 2b data for berobenatide, a once-monthly GLP-1 injection showing ~15% body weight loss in trials The drug could be the first monthly obesity therapy in its class, competing against weekly options like Wegovy and Zepbound Pfizer plans 20+ trials in obesity… Read More »Pfizer (PFE) Stock Rises as Monthly Weight-Loss Drug Data Impresses


















































































